Stock Valuation Discrepancies
Recent Stock Gains Raise Questions as Valuations Diverge Across Major Companies
Anonymous
Key Points
1
Plexus shares were trading at $263.33 on Sept. 22, 2026, within a 52-week range of $132.03 to $307.06. Insiders sold $24.2 million of shares over the previous 12 months, with no reported insider purchases.
2
TD SYNNEX reported $4.85 in quarterly earnings per share in its most recent results, beating the $4.14 consensus estimate by $0.71; revenue reached $19.57 billion, up 31% year over year and above the $16.80 billion consensus forecast.
3
TD SYNNEX’s stock had risen 87.5% year to date, while its trailing P/E of 20.0 was 27% above its five-year median of 15.7. Insiders sold $44.2 million of shares over the prior 12 months and made no reported purchases.
4
Synopsys shares were trading at $401.85 after a 4.4% daily gain, compared with a 52-week high of $539.48 and low of $362.55. Insiders sold $56.0 million of shares over the past year, with no reported insider buying; the stock’s forward P/E was 22.7, well below its trailing P/E of 71.0.
Four major stocks show sharp divergence between share prices and underlying fundamentals, raising questions about whether recent gains are justified. TD SYNNEX surged 87.5% year-to-date after beating earnings estimates by 18% in its most recent quarter, yet trades 62% above GuruFocus' estimated fair value. Plexus holds a strong 89 out of 100 financial strength score but trades 57.8% above intrinsic value. Synopsys stands alone as the bargain, trading 38.8% below fair value despite a 14.4% year-to-date decline. Across all three overvalued stocks, insiders sold over $124 million in shares in the past year and made zero purchases.
TD SYNNEX Surges on Strong Earnings but Looks Expensive
TD SYNNEX reported $4.85 in quarterly earnings per share on September 24, beating the consensus forecast of $4.14 by 18%. Revenue hit $19.57 billion, up 31% year-over-year and well above the $16.80 billion projection according to GuruFocus. The company projects fourth-quarter earnings of $5.90 per share and revenue of $22.2 billion. Yet despite this strength, GuruFocus says the stock is overvalued at 62% above its intrinsic worth estimate.
The stock's trailing price-to-earnings ratio of 20.0 stands 27% above its five-year median of 15.7. TD SYNNEX insiders sold $44.2 million of shares over the past 12 months with no reported purchases. This liquidation pattern—seen across executives at multiple levels—signals internal concern about whether current prices can hold.
Plexus Scores Well but Stock Soars Past Fair Value
Plexus trades at $263.33 as of September 22, near the upper end of its 52-week range of $132.03 to $307.06. The electronics manufacturing company has impressive fundamentals—GuruFocus rates it 89 out of 100 on its Financial Strength & Profitability Score. Yet that quality doesn't justify the valuation. GuruFocus estimates the stock is 57.8% above its intrinsic value, making it one of the market's most overextended mid-cap stocks.
Company insiders sold $24.2 million in shares over the past 12 months. No insider buying was reported during the same period. The sustained selling by executives—people with the best view of business health—suggests they see limited upside at current prices.
Synopsys Offers Rare Discount Despite Year-to-Date Slump
Synopsys rebounded 4.4% on September 22 to close at $401.85, but the electronic design automation software maker remains down 14.4% year-to-date from its 52-week high of $539.48. This weakness has created an unusual opportunity: GuruFocus estimates the stock trades 38.8% below fair value. The forward price-to-earnings ratio of 22.7 shows how dramatically earnings expectations have improved relative to current pricing.
Like other insiders on this list, Synopsys executives have sold heavily—$56.0 million over 12 months—with no purchases. The insider selling appears tied to typical executive diversification rather than fundamental distress. The stock's forward P/E of 22.7 versus trailing P/E of 71.0 signals the market is pricing in sharp earnings growth ahead.
Syndax Pharmaceuticals Cheap by Sector, Expensive by Fundamentals
Syndax Pharmaceuticals gained 21.2% over the past year and trades at 6.4 times sales—below the biotech sector average. Yet GuruFocus' valuation framework still calls the stock expensive relative to revenue, cash burn and execution risk. The clinical-stage biopharmaceutical company faces typical biotech headwinds: high operating costs and no guarantee of commercial success.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
34
Articles
78
Reach
112
A
AnonymousAuthor
